Home » Newsletters » BioWorld Science

BioWorld Science

July 15, 2014

View Archived Issues

Merck & Co. patents new Hdm2 inhibitors for cancer

DemeRx synthesizes novel nAChR antagonists for pain and addictions

FDA approves Medac's autoinjectable subcutaneous methotrexate product

Scientists at Zenith Epigenetics disclose new BET bromodomain inhibitors

Gilead Sciences enrolls patients in phase Ib trial of GS-9857 in HCV

Merck & Co. to begin phase I trial of MK-8189

XMetA demonstrates efficacy in animal models of diabetes

Enrollment begins in phase I study of KHK-2823 in AML or myelodysplastic syndrome

FDA responds to Salix's appeal regarding Relistor sNDA

Researchers at Merck & Co. prepare novel glucokinase activators

Compugen identifies new immunomodulatory proteins

Researchers at Vertex design novel FimH inhibitors

Results of a first-in-human study of Axon's novel tau vaccine

Merck & Co. presents new SYK inhibitors

Gilead divulges novel PI3Kdelta inhibitors

NPT-088, a dimeric fusion protein for the treatment of AD

FDA grants orphan drug status to siponimod for dermatomyositis

Aerie initiates phase III registrational program for Rhopressa in glaucoma

G-Pen shows promising results in a phase II trial

FDA grants priority review to Avastin sBLA

Alcobra completes enrollment in phase III trial of MDX for adult ADHD

Anthera acquires Sollpura from Lilly

Clementia initiates phase II study of palovarotene for FOP

TauRx achieves target enrollment in first phase III study of LMTX for Alzheimer's

Targacept reports topline results from phase IIb study of TC-1734

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
Deals and an M&A strengthen end-of-year numbers
BioWorld
Two large deals and an acquisition, totaling about $4.64 billion in all, are helping wrap up what’s turning out to be a strong year. Through the first 11 months...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
Radiopharm Theranostics’ RAD-101 meets brain metastases endpoints
BioWorld
Radiopharm Theranostics Ltd.’s radiotracer RAD-101 met the primary endpoint in 92% of patients in the phase IIb imaging trial in brain metastases, according to...